NGN Capital is a private equity general partner firm with offices in Germany and United States.
Exosome Diagnostics, a liquid biopsy platform that enables non-invasive diagnosis of serious diseases, raised $60m in Series B financing.
Exosome Diagnostics, a developer of biofluid-based molecular diagnostics, completed a $17.6m Series B round from NGN Capital and others.
Medical test developer Exosome Diagnostics has closed $27m from Arcus Ventures, NGN Capital, Forbion Capital and others.
Read more news concerning NGN Capital
A sampling of NGN Capital portfolio companies:
View all of the investments in their portfolio
Registration is fast, free and easy
Already a member?